Sana Biotechnology Inc. (SANA)
NASDAQ: SANAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SANA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $476.42M
- EPS (TTM)
- -$0.52
- Dividend yield
- None
- 52-week range
- 1.57 – 5.49
- Day range
- 1.57 – 1.75
- Volume / Avg
- 4.45M / 3.30M
- Beta
- —
- Shares outstanding
- 299.63M
52-week range
SANA stock today
Sana Biotechnology (SANA) closed at $1.59 on Nov 20, down 8.62% (-$0.15), versus the S&P 500's 3.70% decline. Shares are 71.0% below their 52-week high of $5.49, set on Dec 4, 2025 and 1.6% above the 52-week low of $1.57, near the bottom of the past year's range. SANA is down 60.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 51.7%.
Sana Biotechnology has posted a net loss over the last twelve months (EPS of -$0.52), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Sana Biotechnology
Company profileSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Steven D. Harr M.D.
- Headquarters
- Seattle, WA
- Employees
- 142
- IPO year
- 2021
- Website
- sana.com
Financial highlights
Full financialsSana Biotechnology reported a net loss of $244.2 million, compared with a loss of $266.8 million a year earlier. Diluted earnings per share came in at -$0.96.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-244.17M | $-266.76M | $-283.25M | $-269.48M | $-355.93M |
| EPS (diluted) | $-0.96 | $-1.16 | $-1.46 | $-1.43 | $-2.14 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$8.57+438.99%
- Strong buy 2
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.07 vs $-0.18
- Surprise
- +138.89%
SANA news
All SANA newsSana Biotechnology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RGNXREGENXBIO Inc. | 7.16 | -0.28% | $473.44M | vs SANA |
| DNAGinkgo Bioworks Holdings Inc. Class A | 7.46 | -9.02% | $483.54M | vs SANA |
| FENCFennec Pharmaceuticals Inc. | 13.09 | -2.68% | $462.14M | vs SANA |
| VALNValneva SE ADR | 5.16 | -3.82% | $490.86M | vs SANA |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs SANA |
| IRLAIRulya Therapeutics Inc. | 39.88 | -0.15% | $432.36M | vs SANA |
| PROKProKidney Corp. Class A | 1.04 | -1.89% | $415.21M | vs SANA |
| TECXTectonic Therapeutic Inc. | 20.73 | -1.47% | $405.26M | vs SANA |
Indexes, lists and sector
Sana Biotechnology stock FAQ
What is Sana Biotechnology's stock price today?
SANA last traded at $1.59 as of Nov 20, 4:00 PM EST, down 8.62% on the day. Prices are delayed at least 15 minutes.
Who is Sana Biotechnology's CEO?
Dr. Steven D. Harr M.D. is the chief executive officer of Sana Biotechnology Inc., which has about 142 employees.
What is the SANA 52-week high?
The 52-week high for SANA is $5.49 and the 52-week low is $1.57. The stock is currently 71.0% below its high.